CYTK vs DXCM · rev $28.6M vs P/E 63, rev $2.50B
Cytokinetics Inc (CYTK) versus DexCom Inc (DXCM) — a side-by-side from cached financials, not a winner call.
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
DexCom Inc (DXCM) is a medical devices company listed on US.
Latest reported CYTK revenue for 2026-06-30 was $28.6M. Net income was -$198.8M. Revenue was up 47.9% from 2026-03-31 to 2026-06-30. CYTK currently screens at market cap $4.05B.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
CYTK currently screens at market cap $4.05B. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Not investment advice. Open the CYTK and DXCM stock pages for the full models.
Not investment advice.